Orchid Pharma announced its Q2 FY25 results, reflecting strong growth in revenue and profitability. The company continues to benefit from efficient cost management and operational improvements, leading to substantial gains in profit.
Key Financial Highlights for Q2 FY25:
- Revenue from Operations: ₹222.7 crore, a 12% Year-over-Year (YoY) increase from ₹198.8 crore in Q2 FY24.
- EBITDA: ₹37.5 crore, showing a 20% YoY growth from ₹31.2 crore in Q2 FY24, with EBITDA margin improving to 17%.
- Profit Before Tax (PBT): ₹25.6 crore, up 26% YoY from ₹20.3 crore.
- Net Profit (PAT): ₹25.6 crore, a significant 26% increase YoY from ₹20.3 crore in Q2 FY24.
Half-Year Highlights (6M FY25):
- Revenue: ₹467.1 crore, a 22% increase compared to the same period last year.
- EBITDA: ₹78.6 crore, up 44% from ₹54.7 crore in 6M FY24.
- PAT: ₹54.7 crore, a 76% rise YoY.
Orchid Pharma’s robust results underline its strategic focus on growth and profitability, positioning the company strongly for sustained performance in the pharmaceutical sector.
TOPICS:
Orchid Pharma